《控制近视进展药物临床研究技术指导原则》(征求意见稿)

2020-08-27 国家药品监督管理局药品审评中心(CDE) CDE

近视已成为全球最严重的公共健康问题之一。近年来,随着社会生活和环境因素的显著变化,我国的近视和高度近视患病率均不断攀升,且呈现低龄化、重度化趋势。为进一步规范和指导该领域新药科学研发和评价,我中心起草

中文标题:

《控制近视进展药物临床研究技术指导原则》(征求意见稿)

发布日期:

2020-08-27

简要介绍:

近视已成为全球最严重的公共健康问题之一。近年来,随着社会生活和环境因素的显著变化,我国的近视和高度近视患病率均不断攀升,且呈现低龄化、重度化趋势。为进一步规范和指导该领域新药科学研发和评价,我中心起草了《控制近视进展药物临床研究技术指导原则》的征求意见稿,现向社会各界公开征求意见。
       社会各界如有意见,请于2020年9月23日17:00前通过电子邮箱反馈。
       联系人:谢松梅 赵聪
       邮箱:xiesm@cde.org.cn,zhaoc@cde.org.cn
                                                                                                                           国家药品监督管理局药品审评中心
                                                                                                                                         2020年8月24日

相关资料下载:
[AttachmentFileName(sort=1, fileName=《控制近视进展药物临床研究技术指导原则》(征求意见稿).docx)] GetToolGuiderByIdResponse(projectId=1, id=bd9ff1c001963a2d, title=《控制近视进展药物临床研究技术指导原则》(征求意见稿), enTitle=, guiderFrom=CDE, authorId=0, author=, summary=近视已成为全球最严重的公共健康问题之一。近年来,随着社会生活和环境因素的显著变化,我国的近视和高度近视患病率均不断攀升,且呈现低龄化、重度化趋势。为进一步规范和指导该领域新药科学研发和评价,我中心起草, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心(CDE), associationIntro=国家药品监督管理局药品审评中心(CDE), copyright=0, guiderPublishedTime=Thu Aug 27 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">近视已成为全球最严重的公共健康问题之一。近年来,随着社会生活和环境因素的显著变化,我国的近视和高度近视患病率均不断攀升,且呈现低龄化、重度化趋势。为进一步规范和指导该领域新药科学研发和评价,我中心起草了《控制近视进展药物临床研究技术指导原则》的征求意见稿,现向社会各界公开征求意见。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 社会各界如有意见,请于2020年9月23日17:00前通过电子邮箱反馈。</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 联系人:谢松梅 赵聪</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 邮箱:xiesm@cde.org.cn,zhaoc@cde.org.cn</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 国家药品监督管理局药品审评中心</span><br style="color: #333333;" /><span style="color: #333333;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2020年8月24日</span></p>, tagList=[TagDto(tagId=26642, tagName=指导原则)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5260, appHits=107, showAppHits=0, pcHits=823, showPcHits=5153, likes=1, shares=3, comments=4, approvalStatus=1, publishedTime=Tue Sep 01 10:34:27 CST 2020, publishedTimeString=2020-08-27, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Tue Sep 01 10:33:55 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 18:56:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《控制近视进展药物临床研究技术指导原则》(征求意见稿).docx)])
《控制近视进展药物临床研究技术指导原则》(征求意见稿).docx
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=909051, encodeId=5913909051c8, content=插眼等更新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00075443992, createdName=ms4000001622968144, createdTime=Fri Dec 18 09:12:15 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890276, encodeId=f46c8902e6f5, content=好期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=12364763m85暂无昵称, createdTime=Mon Oct 05 21:36:18 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881977, encodeId=09308819e7bb, content=<a href='/topic/show?id=a46a94293c9' target=_blank style='color:#2F92EE;'>#近视#</a>关键有没有治疗近视的药物,目前只有器械也不一定真正有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94293, encryptionId=a46a94293c9, topicName=近视)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 02 07:19:15 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-12-18 ms4000001622968144

    插眼等更新

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=909051, encodeId=5913909051c8, content=插眼等更新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00075443992, createdName=ms4000001622968144, createdTime=Fri Dec 18 09:12:15 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890276, encodeId=f46c8902e6f5, content=好期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=12364763m85暂无昵称, createdTime=Mon Oct 05 21:36:18 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881977, encodeId=09308819e7bb, content=<a href='/topic/show?id=a46a94293c9' target=_blank style='color:#2F92EE;'>#近视#</a>关键有没有治疗近视的药物,目前只有器械也不一定真正有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94293, encryptionId=a46a94293c9, topicName=近视)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 02 07:19:15 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-10-05 12364763m85暂无昵称

    好期待

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=909051, encodeId=5913909051c8, content=插眼等更新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00075443992, createdName=ms4000001622968144, createdTime=Fri Dec 18 09:12:15 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890276, encodeId=f46c8902e6f5, content=好期待, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/3bf2334e50604c0a86fdd028570a8bdc/ebee9ab0697b40f3b72b68fa7c659ee7.jpg, createdBy=6d582405709, createdName=12364763m85暂无昵称, createdTime=Mon Oct 05 21:36:18 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881977, encodeId=09308819e7bb, content=<a href='/topic/show?id=a46a94293c9' target=_blank style='color:#2F92EE;'>#近视#</a>关键有没有治疗近视的药物,目前只有器械也不一定真正有用。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94293, encryptionId=a46a94293c9, topicName=近视)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 02 07:19:15 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-09-02 lovetcm

    #近视#关键有没有治疗近视的药物,目前只有器械也不一定真正有用。

    0